Ovid Therapeutics has shown a marked moderation in its operating losses and net income deficits over the past four years, driven by disciplined expense management amid ongoing investment in its pipeline. The company’s focus on small molecule therapies for neuronal hyperexcitability conditions—including novel GABA-AT inhibitors and KCC2 activators—positions it distinctively within CNS drug development. The recent $60 million capital raise enhances liquidity, providing operational runway to progress key clinical trials and regulatory milestones. Critical risks include continued capital needs and regulatory uncertainties inherent to biopharmaceutical development.